RCT: Tremelimumab does not improve survival in advanced melanoma

Source: JCO Area: News The Journal of Clinical Oncology has featured a study evaluating the cytotoxic T lymphocyte-associated antigen-4-blocking monoclonal antibody tremelimumab compared with standard-of-care chemotherapy in patients with advanced melanoma.   The phase III trial involved 655 patients with treatment-naive, unresectable stage IIIc or IV melanoma who were randomised to receive tremelimumab (15 mg/kg once every 90 days) or physician's choice of standard-of-care chemotherapy (temozolomide or dacarbazine). Tumour responses were assessed every 90 days (one cycle) in patients treated with tremelimumab, every 42 days (two cycles) in patients treated with dacarbazine, and every 56 days (two cycles) in patients treated with temozolomide. In both study arms, there was a planned assessment of tumour response at 6 months to determine PFS rate at this time point.   The researchers reported that at the time of planned interim analysis, after 340 deaths had occurred, median OS was ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news